Compare ANNX & BSVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | BSVN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.1M | 393.6M |
| IPO Year | 2020 | 2018 |
| Metric | ANNX | BSVN |
|---|---|---|
| Price | $6.29 | $43.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $16.50 | ★ $53.33 |
| AVG Volume (30 Days) | ★ 2.8M | 16.2K |
| Earning Date | 03-02-2026 | 01-15-2026 |
| Dividend Yield | N/A | ★ 2.50% |
| EPS Growth | N/A | ★ 19.43 |
| EPS | N/A | ★ 4.54 |
| Revenue | N/A | ★ $95,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.23 |
| P/E Ratio | ★ N/A | $9.50 |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $1.29 | $32.49 |
| 52 Week High | $6.83 | $50.26 |
| Indicator | ANNX | BSVN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.46 |
| Support Level | N/A | $42.07 |
| Resistance Level | N/A | $42.99 |
| Average True Range (ATR) | 0.00 | 0.99 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 0.00 | 95.60 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.